================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report: January 19, 2005
Date of earliest event reported: January 18, 2005
PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware 1-3619 13-5315170
(State or other (Commission File (I.R.S. Employer
jurisdiction of incorporation) (Number) Identification No.)
235 East 42nd Street 10017
New York, New York (Zip Code)
(Address of principal executive offices)
Registrant's telephone number, including area code:
(212) 573-2323
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the obligation of the registrant under any of the
following provisions:
[ ] Written communication pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
Item 2.02 Results of Operations and Financial Condition
On January 19, 2005, Pfizer Inc. (the "Company" or "Pfizer") issued a press
release announcing its financial results for the fourth quarter of 2004. The
information contained in the press release is deemed to be "filed" under the
Securities Exchange Act of 1934 as Exhibit 99 to this report, and such press
release is incorporated herein by reference.
Item 2.06 Material Impairments
On January 18, 2005, the Company determined that an indefinite-lived intangible
asset relating to Depo Provera (Depo), a long-acting injectable contraceptive
that was acquired in connection with our acquisition of Pharmacia Corporation in
April 2003, has become impaired due to the unexpected entrance of a generic
competitor in the U.S. market in the latter part of 2004 and, as previously
announced, a labeling change for the addition of more prominent wording in a
"black boxed" warning noting that women who use Depo may lose significant bone
mineral density. The Company recorded a non-cash charge of $691 million ($420
million net of tax) in the fourth quarter of 2004 as a result of the impairment.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits
Exhibit 99 - Press Release of Pfizer Inc. dated January 19, 2005, reporting
Pfizer's financial results for the fourth quarter of 2004.
Exhibit 99 is deemed to be "filed" under the Securities Exchange
Act of 1934 in this Current Report on Form 8-K.
SIGNATURE
Under the requirements of the Securities Exchange Act of 1934, the registrant
has caused this report to be signed on its behalf by the authorized undersigned.
PFIZER INC.
By: /s/ Margaret M. Foran
-------------------------------
Margaret M. Foran
Title: Vice President-Corporate
Governance and Secretary
Dated: January 19, 2005
EXHIBIT INDEX
Exhibit No. Description
----------- --------------------------------------------------------------
99 Press Release of Pfizer Inc. dated January 19, 2005, reporting
Pfizer's financial results for the fourth quarter of 2004.